Oligodendroglioma

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Freitag, November 10, 2023
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Neurology, Other Science, Research, Science, Clinical Trials, CNS, Neoplasm, Vancouver Convention Centre, Safety, Annual general meeting, PST, Quality, Radiosurgery, Pakistan Society of Neuro-Oncology, Barrier, American Brain Tumor Association, TRIDENT, GBM, Chemoradiotherapy, Patient, TMZ, TTF, Radiation, Alternating electric field therapy, Quality of life, Lung cancer, Neuro, Biomarker, Trial of the century, METIS, Survival, TIGER, Central nervous system, Immunotherapy, Skin, Oligodendroglioma, SNO, NSCLC, Medical imaging, Pharmaceutical industry, Communications satellite, Glioblastoma

The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.

Key Points: 
  • The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.
  • Long-term global post-marketing surveillance data from pediatric, adult and elderly patients with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy.
  • 7:30 p.m. PST on Friday, Nov. 17
    Adopting Tumor Treating Fields (TTFields) therapy for glioblastoma and other solid cancers: challenges and opportunities.
  • 7:30 p.m. PST on Friday, Nov. 17
    Development of Tumor Treating Fields (TTFields) arrays for treatment of head tumors in mice models.

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Retrieved on: 
Sonntag, Juni 4, 2023
Glioma, The New England Journal of Medicine, Malignancy, BIRC, INDIGO, Oligodendroglioma, Survival, Clinical trial, Enzyme, NDA, Drug, Mutation, Traffic barrier, Brain, PFS, Astrocytoma, ASCO, Patient, HR, Seizure, IDH, Memorial Sloan Kettering Cancer Center, Toxic encephalopathy, FDA, Society, Disease, Medical imaging, Pharmaceutical industry

BOSTON, June 4, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing innovative therapies to the patients we serve, today presented results from the pivotal Phase 3 INDIGO clinical trial investigating vorasidenib, an investigational, oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1/2 enzymes in patients with residual or recurrent isocitrate dehydrogenase 1 or 2 (IDH1/2) mutant low-grade glioma who have been treated with surgery only. INDIGO succeeded in meeting its primary endpoint of progression free survival (PFS) per blinded independent review committee (BIRC) and key secondary endpoint of time to next intervention (TTNI) at the prespecified second interim analysis. The data were presented as a late breaking abstract during the plenary session at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), and simultaneously published in the New England Journal of Medicine.

Key Points: 
  • We look forward to working with the FDA on its review of vorasidenib as a potential therapy in IDH-mutant diffuse glioma."
  • INDIGO is a registration-enabling Phase 3 global, randomized, double-blinded placebo-controlled study of vorasidenib in patients with residual or recurrent grade 2 glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation who have undergone surgery as their only treatment.
  • Of the 331 patients, 172 had oligodendroglioma (88 vorasidenib; 84 placebo) and 159 patients had astrocytoma (80 vorasidenib; 79 placebo).
  • Servier is working to determine timelines for submission of a New Drug Application (NDA) for vorasidenib to the FDA.

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

Retrieved on: 
Dienstag, März 14, 2023
IDH, Clinical trial, Drug, Mutation, Caregiver, Doctor of Philosophy, Late-stage functionalization, IDH1, Progression-free survival, PFS, Patient, Oligodendroglioma, INDIGO, Food and Drug Administration, Glioma, FDA, IDH2, Science, Astrocytoma, Medical imaging, Nursing, Pharmaceutical industry

"Therapeutic progress in the low-grade glioma space has been stagnant for decades.

Key Points: 
  • "Therapeutic progress in the low-grade glioma space has been stagnant for decades.
  • "We are grateful to the patients, caregivers, investigators and study teams who made this remarkable achievement possible through their participation in the INDIGO clinical trial."
  • The Phase 3 INDIGO trial results will be presented at an upcoming medical meeting.
  • Due to the accelerated enrollment and interim efficacy analysis outcome, the INDIGO clinical trial is well ahead of schedule.

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

Retrieved on: 
Dienstag, März 14, 2023
IDH, Clinical trial, Drug, Mutation, Caregiver, Doctor of Philosophy, Late-stage functionalization, IDH1, Progression-free survival, PFS, Patient, Oligodendroglioma, INDIGO, Food and Drug Administration, Glioma, FDA, IDH2, Science, Astrocytoma, Medical imaging, Nursing, Pharmaceutical industry

"Therapeutic progress in the low-grade glioma space has been stagnant for decades.

Key Points: 
  • "Therapeutic progress in the low-grade glioma space has been stagnant for decades.
  • "We are grateful to the patients, caregivers, investigators and study teams who made this remarkable achievement possible through their participation in the INDIGO clinical trial."
  • The Phase 3 INDIGO trial results will be presented at an upcoming medical meeting.
  • Due to the accelerated enrollment and interim efficacy analysis outcome, the INDIGO clinical trial is well ahead of schedule.

Feinstein Institutes, Northwell Use Ultrasound to Treat Brain Tumors in Novel Clinical Trial

Retrieved on: 
Donnerstag, Januar 12, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Brain, Israeli Navy, Feinstein, Feinstein Institute for Medical Research, Credit, Neoplasm, Medical research, Molecular medicine, Medicine, Safety, North Shore University Hospital, Glioblastoma, Patient, Radiation, Neurology, Clinical trial, Northwell Health, Multimedia, SDT, Alpheus, Medical imaging, Oligodendroglioma, MD, Neurosurgery

View the full release here: https://www.businesswire.com/news/home/20230112005272/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005272/en/
    Yehuda Haber (left) speaks with Dr. Michael Schulder about the Alpheus Medical ultrasound clinical trial.
  • (Credit: Feinstein Institutes)
    There are few therapeutic options to treat these recurrences for many patients diagnosed with high-grade gliomas, including glioblastoma.
  • This multi-site clinical trial looks to study the safety and optimal dosage of an investigational novel sonodynamic therapy (SDT) platform, which targets solid body cancers through ultrasound.
  • Schulder’s clinical research on brain tumors produces essential new knowledge to guide future therapeutic strategies.”
    Alpheus Medical is the sponsor of the trial.

Intermountain Healthcare and Las Vegas Raiders Honor Cancer Patients and Survivors During Ceremony with Musician Rachel Platten

Retrieved on: 
Donnerstag, November 10, 2022
GLOBE, Hospital, Chase Garbers, Raider, Health, Survivor, American Childhood Cancer Organization, Ewing's sarcoma, Las Vegas Raiders, Bone, Neoplasm, Emma, Family, Volleyball, Monti, Diagnosis, Frazier Healthcare Partners, Cancer, Zárate, Brain, Time, Intermountain Healthcare, Friends, A. J. Cole, Patient, Breast cancer, Physician, Lymphoma, Ageing, St. George Regional Hospital, Hodgkin lymphoma, Football, Allegiant Stadium, Pharmaceutical industry, Medical imaging, Vaccine, Oligodendroglioma, Intermountain

Las Vegas, NV, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intermountain Healthcare and the Las Vegas Raiders honored five cancer survivors last month during the pregame show against Houston at Allegiant Stadium.

Key Points: 
  • Las Vegas, NV, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intermountain Healthcare and the Las Vegas Raiders honored five cancer survivors last month during the pregame show against Houston at Allegiant Stadium.
  • During that pregame performance, five Intermountain Healthcare cancer survivors were recognized in front of an Allegiant Stadium audience of nearly 61,000 fans for their courageous fight.
  • Intermountain Healthcare is the Official Healthcare Partner of the Raiders and a Founding Partner of Allegiant Stadium.
  • Audrey Monti, a Las Vegas mother of two, was an avid runner and indoor cyclist before her breast cancer diagnosis.

Brain Cancer Diagnostics Market Report 2022: Increase in Brain Cancer and Cigarette Smokers Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Dienstag, September 13, 2022
Health, Oncology, Medical Devices, Incidence, COVID-19, Brain, Prevalence, Cancer Research UK, Glioblastoma, CM3, Neoplasm, Meningioma, MRI, SES Platform Services, Growth, American Association, Nuclear magnetic resonance spectroscopy, Ganglioneuroma, PET, Cancer, American Association of Neurological Surgeons, Solution, CT, Ependymoma, Congress of Neurological Surgeons, Craniopharyngioma, Cancer Australia, CNS, H. Lee Moffitt Cancer Center & Research Institute, Astrocytoma, Ageing, Association, EEG, Hospital, Oligodendroglioma, Biopsy, Electroencephalography, MRS, CAGR, Medical imaging

The global brain cancer diagnostics market is expected to grow from US$ 1,639.10 million in 2022 to US$ 7,378.57 million by 2028.

Key Points: 
  • The global brain cancer diagnostics market is expected to grow from US$ 1,639.10 million in 2022 to US$ 7,378.57 million by 2028.
  • The increase in brain cancer worldwide and the rise in cigarette smokers boost the growth of the global brain cancer diagnostics market.
  • Thus, the increase in the prevalence of brain cancer worldwide highly demands brain cancer diagnostic tools.
  • Based on cancer type, the brain cancer diagnostics market is segmented into acoustic neuroma, astrocytomas, craniopharyngiomas, ganglioneuromas, glioblastoma multiforme, ganglioneuroma, meningiomas, ependymomas, oligodendroglioma, low-grade tumors, and others.

Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, April 7, 2022
Health, Pharmaceutical, Benchmark, Neoplasm, Meningioma, Cisplatin, Glioblastoma, Radiation, Schwannoma, Temozolomide, Lists of diseases, Growth, Coronavirus, Patient, Chemotherapy, Glioma, Everolimus, Cancer, Prevalence, Brain, Medulloblastoma, Regeneration, National Brain Tumor Society, Life expectancy, Carmustine, Infection, PNET, Create, Astrocytoma, Anaplastic astrocytoma, Brain tumor, Marketing, Medical imaging, Oligodendroglioma, Bevacizumab

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.

Key Points: 
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib.
  • The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide.
  • Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market.

National Brain Tumor Society Launches DNA Damage Response Consortium with Yale

Retrieved on: 
Dienstag, Februar 22, 2022
Partnership, Yale Cancer Center, Ependymoma, Neoplasm, Yale University, Kate, Awareness, Science, National Brain Tumor Society, Glioblastoma, Brain, Radiology, Cancer, Adult, DNA, Multimedia, Astrocytoma, DDR, Biotechnology, Caregiver, FDA, DNA repair, Patient, NBTS, Research, Doctor of Philosophy, Policy, Mobile phone, Medical imaging, Pharmaceutical industry, Oligodendroglioma

NEWTON, Mass., Feb.22, 2022 /PRNewswire/ --Today, the National Brain Tumor Society (NBTS) announced the launch of its new flagship research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center.

Key Points: 
  • NEWTON, Mass., Feb.22, 2022 /PRNewswire/ --Today, the National Brain Tumor Society (NBTS) announced the launch of its new flagship research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center.
  • "With drugs designed to attack tumors' DDR network already transforming other difficult-to-treat cancers, this strategy needs to be quickly and expertly tested for brain tumor patients," added Kirk Tanner, PhD, Chief Scientific Officer of the National Brain Tumor Society.
  • "NBTS strongly believes that existing and future drugs and combinations discovered and advanced by this consortium have the potential to transform the treatment landscape for brain tumor patients," said David Arons, Chief Executive Officer of the National Brain Tumor Society.
  • Building on over 30 years of experience, the National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers.

New CAP Guideline Improves Testing, Care, for Patients with Diffuse Gliomas

Retrieved on: 
Donnerstag, Februar 17, 2022
Science, Other Science, Radiology, Managed Care, Oncology, Health, Genetics, Other Health, Pathology, Archives of Pathology & Laboratory Medicine, Patient, National academy, Prognosis, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, 2021 Essex County Council election, Doctor of Philosophy, Association for Molecular Pathology v. Myriad Genetics, Inc., World, Diagnosis, Society, College, Oligodendroglioma, IDH, Adult, Development, Leadership, GRADE, Glioma, Neoplasm, WHO, Guideline, Oligoastrocytoma, Astrocytoma, READ, Mutation, National Academy of Medicine, Marie Cassidy, Classification, Disease, CAP, Medical laboratory, American Association, Association, World Health Organization, American Association of Neuropathologists, Medical imaging, Dietary supplement, MD

Diffuse gliomas affect approximately 15,000 people in the US each year and present with widely variable clinical courses and treatment approaches.

Key Points: 
  • Diffuse gliomas affect approximately 15,000 people in the US each year and present with widely variable clinical courses and treatment approaches.
  • Traditionally, diffuse gliomas have been classified by their microscopic properties as astrocytomas, oligodendrogliomas, or oligoastrocytomas ranging from World Health Organization (WHO) grades 2 to 4.
  • With the new CAP guideline, clinical teams now have evidence-based guidance for diffuse glioma molecular testing more broadly, which can help improve the diagnosis, prognosis, and therapeutic care for patients.
  • Offers guidance specific to biomarker testing in pediatric patients with diffuse gliomas.